2 news items
Novocure Reports Presentation Of Clinical Data From Phase 3 METIS Trial; Says Trial Met Its Primary Endpoint, Demonstrating Statistically Significant Improvement In Time To Intracranial Progression
NVCR
3 Jun 24
%. Baseline patient demographics and characteristics were well balanced between arms.
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
NVCR
3 Jun 24
demographics and characteristics were well balanced between arms.
Patients treated with TTFields therapy
- Prev
- 1
- Next